Navigation Links
Januvia Pancreatic Cancer Lawsuits: Bernstein Liebhard LLP Comments on Medical Journal’s Investigation of Incretin Mimetics

New York, New York (PRWEB) June 21, 2013

As Januvia pancreatic cancer lawsuit claims continue to move forward in U.S. courts, Bernstein Liebhard LLP notes that a new investigation by the British Medical Journal is raising serious questions about the safety of type 2 diabetes drugs like Januvia. According to the June 10th report, previously unpublished data indicate that incretin mimetics, the class of medications that includes Januvia, may have harmful effects on the pancreas which were downplayed by their manufacturers. The report also asserts that investigators were denied access to raw data that might have resolved doubts about the safety of Januvia and other incretin mimetics.*

"The findings of this investigation would appear to lend weight to claims made by plaintiffs who have filed Januvia lawsuits,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free legal evaluations to alleged victims of Januvia pancreatic cancer, Januvia pancreatitis or Januvia thyroid cancer.

Januvia Lawsuits
Court documents indicate that Merck & Co. has been named in a number of Januvia lawsuits that allege the drug caused users to develop pancreatic cancer, pancreatitis or thyroid cancer. The U.S. Judicial Panel on Multidistrict Litigation (JPML) is scheduled to hear Oral Arguments on July 25, 2013, regarding the proposed establishment of a multidistrict litigation for all federally-filed lawsuits involving Januvia and other incretin mimetics. (In Re: Incretins Products Liability, Sales and Marketing Litigation, MDL 2452, JPML)

The U.S. Food & Drug Administration (FDA) announced in March that it was investigating incretin mimetics after results from an unpublished study indicated these medications might cause pre-cancerous changes in the pancreas.** Earlier this month, the American Diabetes Association called for an independent review of all incretin mimetics to provide clarity to patients and health care providers in light of the recent controversy.***

The British Medical Journal investigation is not the first time concerns have arisen regarding the possible pancreatic side effects associated with Januvia and similar drugs. In 2009, a caution regarding a potential Januvia pancreatitis risk was added to the drug’s label after the FDA became aware of 88 post-marketing cases of acute pancreatitis in patients taking the drug.**** In 2011, a study published in Gastroenterology found that use of Januvia appeared to increase the risk of pancreatitis and pancreatic cancer. Two cases of thyroid cancer were also reported in the patients who took Januvia.****

Alleged victims of Januvia pancreatic cancer, thyroid cancer or pancreatitis may be entitled to compensation for medical bills, lost wages, pain and suffering and more. To learn more about filing a Januvia lawsuit, please visit Bernstein Liebhard LLP’s website. For more information, please call 800-511-5092.

*; BMJ, June 10, 2013
***, ADA, June 10, 2013
****; September 25, 2009
*****, Gastroenterology, February 21, 2011

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 10 consecutive years.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016

ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Januvia Lawsuit News: Bernstein Liebhard LLP Comments on Recent FDA Meeting to Discuss Safety of Januvia and Other Incretin Mimetics
2. Rottenstein Law Group LLP Comments on Drugmakers’ Cooperation With Safety Review of Byetta, Januvia, Victoza
3. Januvia Lawsuit News: Rottenstein Law Group LLP Comments on Doctor’s Doubts About Januvia
4. Januvia Lawsuits Consultations Now Offered by the Berman Law Group, Januvia Lawyers and Compensation Experts
5. DrugRisk Adds New Pancreatic Cancer Warning for Diabetes Drug Januvia
6. Pancreatic Cancer Correlation to Type 2 Diabetes Drugs Januvia and Byetta, New Studies Find Possible Connection
7. DrugRisk Announces Addition of Januvia Cancer Resource Center
8. Byetta Pancreatic Cancer Lawsuit News: Bernstein Liebhard LLP Comments on BMJ Investigation Finding Incretin Mimetic Risks Were Downplayed
9. Pancreatic Cancer Survivor and Author Bob Brown Releases Highly Anticipated New Book "Ride of My Life"
10. Diabetes Drug Byetta Caused Arkansas Man’s Pancreatic Cancer and Resulting Injuries, Alleges Lawsuit Filed by Parker Waichman LLP and Co-Counsel
11. Byetta Lawyers at Gilman Law, a Leading Pharmacy Law and Defective Drug Plaintiffs’ Law Firm, Troubled by Growing Byetta Pancreatic Cancer Reports
Post Your Comments:
(Date:11/27/2015)... ... November 27, 2015 , ... ... 27th edition of USA Today in Atlanta, Dallas, New York, Minneapolis, South Florida, ... The digital component is distributed nationally, through a vast social media strategy and ...
(Date:11/27/2015)... ... November 27, 2015 , ... Consistent with the Radiology ... Building Better Radiology Marketing Programs meeting will showcase some of the best ... at Caesars Palace in Las Vegas with a pre-conference session on a collaborative ...
(Date:11/27/2015)... ... November 27, 2015 , ... The moment you ... for not only fulfilling the needs of advisers and clients but going above ... and providing top-tier customer service. However, there's always room for improvement, which is ...
(Date:11/27/2015)... ... 2015 , ... The men and women on this list ... the country. They have overseen financial turnarounds, shown commitment to their community through ... as a whole through their advocacy and professional efforts. , Becker's Hospital Review ...
(Date:11/27/2015)... ... November 27, 2015 , ... Indosoft Inc., developer ... incorporation of Asterisk 11 LTS (Long Term Support) into its Q-Suite 5.10 product ... Q-Suite 5.10 up-to-date with a version of Asterisk that will receive not only ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... DUBLIN , November 26, 2015 ... has announced the addition of the  ... in the European Cell Surface Marker ... Emerging Opportunities"  report to their offering.  ... announced the addition of the  "2016 ...
(Date:11/25/2015)...  Amgen (NASDAQ: AMGN ) today announced the ... the United States (U.S.) Food and ... to Humira ® (adalimumab). Amgen believes this submission ... FDA and represents Amgen,s first BLA submission using the ... M.D., executive vice president of Research and Development at ...
(Date:11/25/2015)... 25, 2015 AAIPharma Services Corp./Cambridge Major ... at least $15.8  Million to expand its laboratories ... . The expansion will provide additional office ... growing demands of the pharmaceutical and biotechnology markets. ... will provide up to 40,000 square feet of ...
Breaking Medicine Technology: